Figure 4.

Impact of parameter assumptions on the incremental cost-effectiveness ratio. Dashed line represents the commonly cited cost-effectiveness threshold in Norway (ie, $83 000 per quality-adjusted life-year gained), and the shaded region represents the upper and lower bounds of commonly cited cost-effectiveness thresholds. The base scenario assumes comprehensive vaccine benefit to multiple human papillomavirus (HPV)–related conditions (cervical, vaginal, vulvar, anal, penile, and oropharyngeal cancer; genital warts; and juvenile-onset recurrent respiratory papillomatosis), 50% coverage for catch-up vaccination (ages 18–26 years), $75 per vaccine dose, and the lower bound of vaccine protection among women previous exposed to vaccine-targeted HPV types.